Federal health regulators have concluded their investigation into the passing of two individuals at paid plasma clinics in Manitoba, determining that the 2 deaths after giving plasma in Winnipeg were not linked to the donation process. Health Canada announced Friday that its assessment found no evidence of machine malfunction, confirming that the equipment used during the procedures performed as expected.
The findings bring a technical resolution to a series of events that sparked international headlines and prompted Manitoba’s health leadership to question the safety and oversight of for-profit plasma collection. Even as the regulator cleared the donation process itself, the investigation has nonetheless triggered a sweeping set of new restrictions on the operator involved, citing systemic failures across its Canadian network.
According to Mark Johnson, a spokesperson for Health Canada, the agency’s assessment was comprehensive, evaluating the medical histories of the donors, the specific timing of the events, and any incidents that occurred during the plasma collection. Johnson noted that any further inquiries regarding the specific clinical causes of death fall under the jurisdiction of the province’s chief medical examiner.
The Timeline of Events in Winnipeg
The investigation was launched following two fatal adverse reactions at facilities operated by Grifols, a Spanish-based company specializing in plasma-derived medicines. The first incident occurred on October 25, 2025, involving 22-year-traditional Rodiyat Alabede. Friends of Alabede reported that the young woman’s heart stopped while she was donating plasma at the Grifols centre on Taylor Avenue.
A second death occurred on January 30, 2026, at a separate Grifols location on Innovation Drive, situated near the University of Manitoba. While fewer details have been released regarding the second individual, the proximity and nature of the incidents led to significant public concern and political scrutiny.
| Date | Event | Location |
|---|---|---|
| Oct 25, 2025 | Death of Rodiyat Alabede (22) | Grifols Taylor Avenue |
| Jan 30, 2026 | Second reported donor death | Grifols Innovation Drive |
| Recent (Wed) | New conditions imposed on 16 sites | National (Grifols) |
| Recent (Fri) | Health Canada clears donation process | Federal Assessment |
Systemic Deficiencies and Regulatory Crackdown
Although the deaths were not linked to the donation process, Health Canada revealed that the operator, Grifols, has struggled with “recurring, systemic deficiencies” across its network. The federal regulator has imposed strict new terms and conditions on 16 of its collection centres across Canada to ensure “sustained compliance” with federal Blood Regulations.
The new mandates are designed to slow down operations to prioritize safety. Specifically, Grifols must:
- Reduce the number of daily appointments to ensure staff can strictly follow all safety procedures.
- Reassess the minimum number of fully trained staff required for each position.
- Conduct rigorous reviews of donor files before updating eligibility status.
In a notable distinction, Health Canada clarified that the Innovation Drive location—officially known as Grifols Canada Plasma II Inc.—is not subject to these specific new rules. This is because the site operates under a separate licence and maintains its own independent quality management system.
Political Friction and Oversight Gaps
The handling of these cases has created tension between federal and provincial authorities. Manitoba Health Minister Uzoma Asagwara expressed concern over a communication gap, questioning why the province was not notified of the October death until after the second fatality occurred in January.
Health Canada defended the delay, explaining that adverse events in plasma donation are rare, and there was previously no “standard practice” for how or when to share such information with provincial ministers. However, the incident has led Minister Asagwara to consider the possibility of banning paid plasma donation within the province entirely.
Further complicating the matter, Health Canada confirmed that inspections of both Winnipeg sites uncovered several “non-compliant issues.” The regulator declined to specify the nature of these violations, stating that the inspections are still ongoing.
The Economics of Paid Plasma
The controversy highlights the complexities of the for-profit plasma industry. Unlike voluntary blood donation, paid plasma centres compensate donors for their time and biological material, which is then used to create life-saving medicines. This model relies heavily on strict “donor eligibility assessments” to ensure that the process is safe for the individual and the resulting product is viable.
For many donors, particularly international students or low-income residents, the payments are a significant draw. This makes the regulatory oversight of “donor eligibility” a critical safeguard against health risks.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional regarding the safety of plasma donation.
The next phase of the process will likely involve the release of the chief medical examiner’s report, which will provide the definitive cause of death for the two donors. Until then, the new operational restrictions on Grifols remain in place as the company works to meet federal compliance standards.
We want to hear from you. Do you believe paid plasma donation should be subject to stricter provincial bans, or is federal oversight sufficient? Share your thoughts in the comments below.
